The global urinary cancer market is forecast to grow at a compound annual growth rate (CAGR) of more than 18% during the forecast period from 2021-2030, and the market value anticipates to reach USD 8700 million by 2030.

Cancer of the urinary tract more commonly affects the urethra, bladder, or renal pelvis. Cystoscopy is the gold standard procedure for the diagnosis of bladder cancer. Another technology, computed tomography (CT) urography, is used in macroscopic hematuria in order to obtain images of the upper urinary tract. There is no known cause of urinary tract cancer, but overuse of catheterized bladders, smoking, chronic inflammation in the urinary tract, and exposure to carcinogenic chemicals are factors that may lead to the development of the disease.

Factors Affecting

The increasing prevalence of bladder cancer is an essential factor driving growth in the world's urinary tract cancer market; the increase in funding from private & government sources for studies, growth in the geriatric population, and growth in R&D activities in healthcare.
During the forecast period, the geriatric population is likely to fuel the market's growth. In elderly individuals, fewer immune cells fight against the cancer tissue in the bladder, making them more prone to urinary tract cancer. A report by the American society of clinical oncology (ASCO) indicated that, as of January 2021, approximately 90% of individuals with bladder cancer are older than 55 years of age. As per the American Cancer Society, 2019, smoking combined with workplace exposure can lead to bladder cancer.
The rising number of approvals for the treatment of urinary tract cancer, the increase in sedentary lifestyles such as smoking, and the rise in exposure to the chemical industry contribute to its growth.
In the forecast period, the risk associated with medications prescribed for urinary tract cancer, such as irritation in the bladder, blood in urine, and infection, is anticipated to restrain the market growth.
Impact Analysis of COVID-19

In the past, the COVID-19 outbreak had negatively impacted the global market for urinary tract cancer. The number of outpatient beds at hospitals and cancer centers is declining, as they focus on selecting only those who require a cystoscopy. It results in the cancellation of many non-essential surgical procedures around the world.

Regional Overview

This market has a dominant position in North America and is forecast to remain so during the forecast period due to the rising prevalence of bladder cancer, increase in healthcare expenditures, the existence of key players, availability of advanced cancer treatments, and advancements in R&D activities in the healthcare sector in the region. However, Asia-Pacific anticipates registering the highest CAGR from 2022 to 2030 due to a rise in urinary tract cancer prevalence, an increasing number of smokers, the government's initiatives, and a growing elderly population.

Leading Companies

The leading prominent companies in the global urinary tract cancer market are:

Astellas Pharma Inc. (Japan)
Bristol-Myers Squibb Company (U.S.)
Eli Lily and Company (U.S.)
Endo International plc. (Europe)
Exelixis, Inc. (U.S.)
GlaxoSmithKline Plc. (GSK) (United Kingdom)
Merck KGaA (Germany)
Novartis AG (Europe)
Pfizer Inc. (U.S.)
Johnson & Johnson (U.S.)
Other Prominent Players
Scope of the Report

The urinary tract cancer market segmentation focuses on Cancer Type, Treatment Type, Distribution Channel, and Region.

Segmentation based on Cancer Type

Bladder Cancer
Urethral cancer
Ureteric and Renal Pelvic Cancer
Segmentation based on Treatment Type

Chemotherapy
Retail Pharmacy
Online Pharmacy
Immunotherapy
Retail Pharmacy
Online Pharmacy
Segmentation based on Distribution Channel

Retail Pharmacy
Online Pharmacy
Segmentation based on Region

North America
The U.S.
Canada
Mexico
Europe
Western Europe
The UK
Germany
France
Italy
Spain
Rest of Western Europe
Eastern Europe
Poland
Russia
Rest of Eastern Europe
Asia Pacific
China
India
Japan
Australia & New Zealand
ASEAN
Rest of Asia Pacific
Middle East & Africa (MEA)
UAE
Saudi Arabia
South Africa
Rest of MEA
South America
Brazil
Argentina
Rest of South America